Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
TVRD
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
zacks.com
10 hours ago
zacks.com
12 hours ago
benzinga.com
13 hours ago
benzinga.com
14 hours ago
businesswire.com
18 hours ago
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
NA
vs NA
Q4.23
N/A
NA
vs NA
Q1.24
N/A
NA
vs NA
Q2.24
N/A
NA
vs NA
Q3.24
N/A
NA
vs NA
Q4.24
N/A
NA
vs NA
Q1.25
N/A
-3.22
vs NA
Q2.25
N/A
-1.00
vs NA
Q3.25
N/A
-1.00
vs NA
Q4.25
N/A
-0.84
vs NA
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
-47%
2.6M vs 4.9M
Q4.24
-52%
1.5M vs 3M
Q1.25
+20%
2.6M vs 2.1M
Q2.25
-100%
NA vs 991K
Return on Equity
QoQ
Q1.23
NA
NA
vs NA
Q2.23
NA
NA
vs NA
Q3.23
NA
NA
vs NA
Q4.23
+7%
0.07
vs -0.33
Q1.24
-103%
-1.03
vs 0.07
Q2.24
-173%
-1.73
vs -1.03
Q3.24
+16%
0.16
vs -1.73
Q4.24
+167%
1.67
vs 0.16
Q1.25
+61%
0.61
vs 1.67
Q2.25
+13%
0.13
vs 0.61
Institutionnal Ownership
QoQ
Q1.23
NA
NA
vs NA
NA
Q2.23
NA
NA
vs NA
NA
Q3.23
NA
NA
vs NA
NA
Q4.23
NA
NA
vs NA
NA
Q1.24
NA
NA
vs NA
NA
Q2.24
NA
NA
vs NA
NA
Q3.24
NA
NA
vs NA
NA
Q4.24
NA
NA
vs NA
NA
Q1.25
NA
NA
vs NA
NA
Q2.25
48
48
vs NA
NA
Relative Strength
TVRD
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
NASDAQ
Unprofitable
Unprofitable
0.10 ( 1.54%)
Relative Strenght
2
Volume Buzz
123%
Earning Acce
Yes
Dist 52w H.
85%Quote Panel
Key Metrics
Forecast
862%2026-Revenue
8%2026-EPS
-862%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
23.33(254.56%)
Number of analyst
3
Last analyst upgrade/downgrade
Raymond James
downgradePrevious: Outperform
2025-10-14
Now: Market Perform
Barclays
downgradePrevious: Overweight
2025-10-13
Now: Negative
Cantor Fitzgerald
downgradePrevious: Overweight
2025-10-13
Now: Neutral
Piper Sandler
downgradePrevious: Overweight
2025-10-13
Now: Neutral